Atenolol/Metoprolol tartrate
Phase 3Small molecule
Atenolol/Metoprolol tartrate is one of 48 small molecule programs targeting Coronary Artery Disease. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
114 competitors in Coronary Artery Disease
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Brilinta
AstraZenecaApproved
Corlanor
AmgenApproved
Crestor
AstraZenecaApproved
Niacor
AbbVieApproved
Ozempic
Novo NordiskApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Glucophage
EMD SeronoApproved
Aggrastat
MMedicure
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- GGødstrup Hospital